GVK BIO, Asia's leading integrated research services provider and Quantitative Solutions (QS), a leading modeling and simulation consultancy to the pharmaceutical and biotech industry, have formed a strategic alliance partnership to develop and market clinical trial outcomes databases in high value disease areas.
* The databases capture summary level data for the clinical safety and efficacy outcomes from publicly available data sources. Models derived from them can be used to characterize the probability distribution of clinical efficacy and tolerability as a function of various treatment and patient factors. * The databases can help companies conduct comparative efficacy and safety analysis, link/scale biomarkers to clinical outcomes, predict/improve trial outcome, and develop product differentiation strategies. * The databases are supported by customization and M&S consulting services provided by GVK Bio and QS, respectively, to ensure maximum flexibility and benefits to our clients GVK BIO will distribute globally existing QS Databases in five indications including Rheumatoid Arthritis & Psoriasis, Chronic HCV, Neuropathic Pain, Osteoporosis (postmenopausal) and Major Depression immediately. GVK BIO and QS plan to jointly develop and market additional databases in Dyslipidemia, Schizophrenia, Alzheimer's, and other indications shortly. . Best regards, Sreeni Sreeni Devidas Ph.D. Vice President Business Development GVK BioSciences 5457 Twin Knolls Road Suite 101 Columbia, MD 21045 Tel: 443-838-6260 Fax: (703) 940 4088 www.gvkbio.com <http://www.gvkbio.com/> Notice: The information contained in this electronic mail message is intended only for the use of the designated recipient. This message is privileged and confidential. and the property of GVK BIO or its affiliates and subsidiaries. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this message in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone +91-40-66929999 and destroy any and all copies of this message in your possession (whether hard copies or electronically stored copies).
